



August 30, 2023

Daniel Fabricant, Ph.D.
Natural Products Association
440 1st Street, NW
Washington, DC 20001

Gretchen DuBeau
Alliance for Natural Health USA
94 Landfill Rd
Edinburg, VA 22824

Re: Docket Number FDA-2023-P-0872

Dear Petitioner:

This letter responds to your citizen petition dated March 7, 2023, under docket number FDA-2023-P-0872, requesting that the Food and Drug Administration (FDA or we) “either (1) determine that β -Nicotinamide Mononucleotide (“NMN”) is not excluded from the definition of a dietary supplement under section 21 U.S.C. § 321(ff)(3) of the Food, Drug, and Cosmetic Act (the “Act”), or (2) commit to exercise enforcement discretion in connection with the marketing and selling of NMN in or as a dietary supplement.”

We are advising you, in accordance with 21 CFR 10.30(e)(2), that we have not reached a decision on your petition within the first 180 days due to competing agency priorities. However, be advised that our staff is evaluating your petition.

Sincerely,

Cara Welch, Ph.D.
Director
Office of Dietary Supplement Programs
Center for Food Safety and Applied Nutrition

CC: Dockets Management Branch, HFA-305

U.S. Food and Drug Administration
Center for Food Safety & Applied Nutrition
5001 Campus Drive
College Park, MD 20740
www.fda.gov